Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure

EJC paediatric oncology Pub Date : 2025-05-07 DOI:10.1016/j.ejcped.2025.100235

Irene Schmid , Allison F. O’Neill , Kenichiro Watanabe , Isabelle Aerts , Sophie Branchereau , Penelope R. Brock , Madhumita Dandapani , Brice Fresneau , Jim Geller , Tomoro Hishiki , Danielle Ingham , Kathelijne Kraal , Milind Ronghe , Greg Tiao , Angela Trobaugh-Lotrario , Arun Rangaswami , Michael J. Sullivan , Jozsef Zsiros , Eiso Hiyama , Marcio Malogolowkin , Marc Ansari

{"title":"Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure","authors":"Irene Schmid , Allison F. O’Neill , Kenichiro Watanabe , Isabelle Aerts , Sophie Branchereau , Penelope R. Brock , Madhumita Dandapani , Brice Fresneau , Jim Geller , Tomoro Hishiki , Danielle Ingham , Kathelijne Kraal , Milind Ronghe , Greg Tiao , Angela Trobaugh-Lotrario , Arun Rangaswami , Michael J. Sullivan , Jozsef Zsiros , Eiso Hiyama , Marcio Malogolowkin , Marc Ansari","doi":"10.1016/j.ejcped.2025.100235","DOIUrl":null,"url":null,"abstract":"<div><div>Malignant liver tumors affecting children and adolescents are rare. In order to adequately study liver tumors occurring in this patient population and establish a more uniform approach to therapy, the three primary liver tumor consortia, SIOPEL (mainly European), COG (mainly North American) and JCCG (Japan), in concert, designed an international prospective clinical trial [PHITT (Paediatric Hepatic International Tumour Trial)/COGAHEP1531/JPLT4 – to be referred to as PHITT from this point forth] for the study of hepatoblastoma and hepatocellular carcinoma in children and adolescents. Recruitment to PHITT has recently concluded. The major results from this trial will be published in the next 2–3 years, therefore in the interim, we sought to provide a consensus statement on evidence-based chemotherapy guidance for hepatoblastoma and hepatocellular carcinoma of all stages.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100235"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJC paediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772610X25000236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Malignant liver tumors affecting children and adolescents are rare. In order to adequately study liver tumors occurring in this patient population and establish a more uniform approach to therapy, the three primary liver tumor consortia, SIOPEL (mainly European), COG (mainly North American) and JCCG (Japan), in concert, designed an international prospective clinical trial [PHITT (Paediatric Hepatic International Tumour Trial)/COGAHEP1531/JPLT4 – to be referred to as PHITT from this point forth] for the study of hepatoblastoma and hepatocellular carcinoma in children and adolescents. Recruitment to PHITT has recently concluded. The major results from this trial will be published in the next 2–3 years, therefore in the interim, we sought to provide a consensus statement on evidence-based chemotherapy guidance for hepatoblastoma and hepatocellular carcinoma of all stages.

查看原文本刊更多论文

PHITT联盟就试验结束后治疗肝母细胞瘤、肝细胞肿瘤（未另行指定）、肝细胞癌和纤维板层癌的儿童临时化疗指南达成全球共识

影响儿童和青少年的恶性肝脏肿瘤是罕见的。为了充分研究该患者群体中发生的肝肿瘤并建立更统一的治疗方法，三个原发性肝肿瘤联盟SIOPEL（主要是欧洲），COG（主要是北美）和JCCG（日本）一致，设计了一项国际前瞻性临床试验[PHITT（儿科肝脏国际肿瘤试验）/COGAHEP1531/JPLT4 -从此简称为PHITT]，用于研究儿童和青少年肝母细胞瘤和肝细胞癌。PHITT的征聘工作最近已结束。该试验的主要结果将在未来2-3年内公布，因此在此期间，我们寻求就肝母细胞瘤和肝细胞癌所有阶段的循证化疗指导提供共识声明。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJC paediatric oncology

CiteScore

0.20

自引率

0.00%

发文量